logo-loader
Aston Martin Lagonda Global Holdings PLC

Aston Martin investors told to pay £19 per share for IPO orders or risk losing out

Aston Martin is set to float on the London Stock Exchange on Wednesday

aston martin
The deadline for orders was 11am GMT on Tuesday

Investors in the initial public offering of Aston Martin Lagonda Global Holdings PLC should be prepared to pay £19 per share or risk losing out, according to terms obtained by Bloomberg.

The deadline for orders was 11am GMT on Tuesday ahead of the London float on Wednesday.

The news comes a day after Aston Martin narrowed the price range for the IPO to £18.5 to £20.0 from £17.50 to £22.50, giving it a potential market value of up to £4.6bn.

READ: Luxury carmaker Aston Martin prices Aston-ishing £5bn London float

The luxury carmaker is selling about 25% of its stock in the float.

“By becoming the only automotive company listed on the London Stock Exchange, Aston Martin Lagonda will provide investors with a fitting opportunity to participate in our future success,” chief executive Andy Palmer said as the IPO was announced in September.

“[Our] track record has created significant interest in the Aston Martin Lagonda offer, and we are pleased to offer shares not only to institutional investors but also to our eligible UK resident employees, customers and members of the Aston Martin Owners Club.”

Quick facts: Aston Martin Lagonda Global Holdings PLC

Price: £4.51

Market: LSE
Market Cap: £1.03 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Hemispherx Biopharma releases 'well tolerated' data for...

Hemispherx Biopharma Inc (NYSEAMERICAN:HEB) CEO Thomas Equels tells Protactive that a final report on its phase 1 trial supporting the safety of using its flagship drug Ampligen as a combination therapy to treat recurrent ovarian cancer found that it was “well tolerated." Equels explains the...

4 minutes ago

2 min read